# QT Imaging Holdings, Inc.: overview QTI · Nasdaq · CIK 1844505 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/qti.md) · [Financials](/companies/qti/financials.md) · [Filings](/companies/qti/filings.md) · [Insiders](/companies/qti/insiders.md) Latest reported revenue: [$7.4m](/filings/0001628280-26-056182.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-056182). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [956](/filings/0001628280-25-051332.md) | [847 d](/filings/0001628280-26-020909.md) | [2,798](/filings/0001628280-26-034381.md) | [3,659](/filings/0001628280-26-056182.md) | [4,192](/filings/0001628280-25-051332.md) | [8,275 d](/filings/0001628280-26-020909.md) | [6,530](/filings/0001628280-26-034381.md) | [7,435](/filings/0001628280-26-056182.md) | | Gross margin | % | [63.3%](/filings/0001628280-25-051332.md) | [47.2% d](/filings/0001628280-26-020909.md) | [64.8%](/filings/0001628280-26-034381.md) | [49.9%](/filings/0001628280-26-056182.md) | [43.0%](/filings/0001628280-25-051332.md) | [38.0% d](/filings/0001628280-26-020909.md) | [40.9%](/filings/0001628280-26-034381.md) | [41.2%](/filings/0001628280-26-056182.md) | | Operating margin | % | [(243.4%)](/filings/0001628280-25-051332.md) | [(242.2%) d](/filings/0001628280-26-020909.md) | [(37.2%)](/filings/0001628280-26-034381.md) | [(28.5%)](/filings/0001628280-26-056182.md) | [(39.4%)](/filings/0001628280-25-051332.md) | [(8.5%) d](/filings/0001628280-26-020909.md) | [(36.0%)](/filings/0001628280-26-034381.md) | [(25.1%)](/filings/0001628280-26-056182.md) | | Net margin | % | [(378.6%)](/filings/0001628280-25-051332.md) | [(411.9%) d](/filings/0001628280-26-020909.md) | [(398.0%)](/filings/0001628280-26-034381.md) | [(109.4%)](/filings/0001628280-26-056182.md) | [(108.7%)](/filings/0001628280-25-051332.md) | [(16.8%) d](/filings/0001628280-26-020909.md) | [(52.2%)](/filings/0001628280-26-034381.md) | [(148.9%)](/filings/0001628280-26-056182.md) | | Diluted EPS | $ per share | [(0.51)](/filings/0001628280-25-051332.md) | not reported | [(1.21)](/filings/0001628280-26-034381.md) | [(0.42)](/filings/0001628280-26-056182.md) | [(0.47)](/filings/0001628280-25-051332.md) | not reported | [(0.25)](/filings/0001628280-26-034381.md) | [(0.75)](/filings/0001628280-26-056182.md) | | Free cash flow | $k | [(1,859) d](/filings/0001628280-25-051332.md) | [(1,280) d](/filings/0001628280-26-020909.md) | [(3,536)](/filings/0001628280-26-034381.md) | [(1,490) d](/filings/0001628280-26-056182.md) | [(879) d](/filings/0001628280-25-051332.md) | [(3,179) d](/filings/0001628280-26-020909.md) | [(3,671)](/filings/0001628280-26-034381.md) | [(5,011) d](/filings/0001628280-26-056182.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001193125-24-075608.md) | [0.0](/filings/0001844505-25-000038.md) | [4.9](/filings/0001628280-26-020909.md) | [18.9](/filings/0001628280-26-020909.md) | | Gross margin | % | not reported | [(234.5%)](/filings/0001844505-25-000038.md) | [54.1%](/filings/0001628280-26-020909.md) | [45.4%](/filings/0001628280-26-020909.md) | | Operating margin | % | not reported | [(12409.8%)](/filings/0001844505-25-000038.md) | [(249.6%)](/filings/0001628280-26-020909.md) | [(23.4%)](/filings/0001628280-26-020909.md) | | Net margin | % | not reported | [(15113.2%)](/filings/0001844505-25-000038.md) | [(184.2%)](/filings/0001628280-26-020909.md) | [(111.4%)](/filings/0001628280-26-020909.md) | | Diluted EPS | $ per share | [(0.60)](/filings/0001193125-24-075608.md) | [(0.64)](/filings/0001844505-25-000038.md) | [(2.13)](/filings/0001628280-26-020909.md) | [(2.01)](/filings/0001628280-26-020909.md) | | Free cash flow | $m | not reported | [(2.7)](/filings/0001844505-25-000038.md) | [(10.1)](/filings/0001628280-26-020909.md) | [(9.1)](/filings/0001628280-26-020909.md) | - Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/qti/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Lynrock Lake LP](/funds/1734341.md) | 2026-06-30 | $4.5m | 1,112,201 | | Reduced −42,387 | | [Alyeska Investment Group, L.P.](/funds/1453072.md) | 2026-06-30 | $2.9m | 702,776 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.5m | 356,448 | | Added +334,522 | | [Bleichroeder LP](/funds/1781002.md) | 2026-06-30 | $1.3m | 316,667 | | Added +150,001 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $551.4k | 135,418 | | Reduced −6,362 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $464.4k | 114,099 | | New +114,099 | | [PERKINS CAPITAL MANAGEMENT INC](/funds/884300.md) | 2026-06-30 | $407.0k | 100,000 | | New +100,000 | | [Stonepine Capital Management, LLC](/funds/1440771.md) | 2026-06-30 | $407.0k | 100,000 | | New +100,000 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $249.7k | 61,353 | | Added +33,009 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $225.2k | 55,340 | | Reduced −14,804 | ## Recent filings [All 430 filings](/companies/qti/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-31 | 16:05 ET | [8-K](/filings/0001628280-26-059577.md) | 5.02 Departure or appointment of officers or directors | 0001628280-26-059577 | | 2026-08-18 | 08:33 ET | [8-K](/filings/0001628280-26-057548.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-057548 | | 2026-08-12 | 16:08 ET | [10-Q](/filings/0001628280-26-056182.md) | Quarterly report, period 2026-06-30 | 0001628280-26-056182 | | 2026-08-12 | 16:07 ET | [8-K](/filings/0001628280-26-056179.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-056179 | | 2026-07-28 | 16:21 ET | [8-K](/filings/0001628280-26-050189.md) | 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-050189 | | 2026-07-02 | 08:01 ET | [DEF 14A](/filings/0001628280-26-046700.md) | Proxy statement, period 2026-07-02 | 0001628280-26-046700 | | 2026-05-21 | 16:06 ET | [8-K](/filings/0001628280-26-037242.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-037242 | | 2026-05-13 | 08:19 ET | [10-Q](/filings/0001628280-26-034381.md) | Quarterly report, period 2026-03-31 | 0001628280-26-034381 | | 2026-05-13 | 08:15 ET | [8-K](/filings/0001628280-26-034379.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-034379 | | 2026-03-25 | 08:13 ET | [8-K](/filings/0001628280-26-020919.md) | 5.02 Departure or appointment of officers or directors | 0001628280-26-020919 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-020909.md), filed Mar 25, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/734c4733-d873-4974-a10c-b3e73b75f486) ## About the filer - CIK: 1844505 - Tickers: QTI, QTIWW - Exchange: Nasdaq - SIC code: 3845 Electromedical & Electrotherapeutic Apparatus - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.